Lantheus (NASDAQ:LNTH – Get Free Report) was downgraded by equities researchers at Brookline Capital Markets from a “strong-buy” rating to a “hold” rating in a report released on Tuesday,Zacks.com reports. Wall Street Zen downgraded shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of Lantheus in a research note on Tuesday, May 26th. Eight investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Lantheus Company Profile(Get Free Report)Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals.